Alpha Tau Medical Ltd (DRTS)
NASDAQ:DRTS
Want to see DRTS full AI Analyst Report?
DRTS Stock Chart & Stats
$8.03
$0.35(10.45%)
At close: 4:00 PM EST
$8.03
$0.35(10.45%)
Day’s Range― - ―
52-Week Range$2.81 - $11.62
Previous CloseN/A
Volume116.73K
Average Volume (3M)884.40K
Market Cap
$785.93M
Enterprise Value$959.04M
Total Cash (Recent Filing)$76.90M
Total Debt (Recent Filing)$13.73M
Price to Earnings (P/E)―
Beta0.85
Next Earnings
Aug 18, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.53
Shares Outstanding88,009,735
10 Day Avg. Volume1,028,559
30 Day Avg. Volume884,404
Financial Highlights & Ratios
PEG Ratio-0.53
Price to Book (P/B)5.17
Price to Sales (P/S)0.00
P/FCF Ratio-12.18
Enterprise Value/Market Cap1.22
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-22.75
Forecast
1Y Price Target
$12.20Price Target Upside51.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.62
Revenue Forecast (FY)$1.27M
Bulls Say, Bears Say
Bulls Say
Regulatory ValidationReceiving Japan marketing approval is a durable regulatory milestone that validates the intratumoral alpha‑radiation approach, establishes a commercial foothold in a major oncology market, and creates a template for real‑world use, clinician adoption, and payer engagement across other indications.
Clinical Proof‑of‑concept Across IndicationsRobust early efficacy and favorable safety in hard‑to‑treat pancreatic and other indications represent durable scientific validation of the platform, supporting regulatory pathways, investigator interest, and potential expansion into combos and multiple tumor types if replicated in larger, controlled studies.
Improved Balance Sheet And Capital RunwayPositive equity, moderate debt levels and a multi‑tens of millions cash position as of year‑end provide a tangible runway to fund ongoing pivotal studies, manufacturing scale‑up and regulatory filing activities, reducing near‑term financing pressure versus earlier periods.
Bears Say
No Commercial RevenueThe company remains pre‑commercial with no product sales and widening annual losses, meaning operating performance is solely dependent on future trial success and approvals; persistent losses increase dilution risk and constrain reinvestment capacity if milestones slip.
Sustained Cash BurnConsistent, worsening operating and free cash outflows create a structural reliance on external funding to sustain pivotal trials and commercialization. This elevates financing risk, can force dilutive capital raises, and may limit strategic flexibility if market access tightens.
Commercialization And Regulatory Execution RiskMarket access remains limited and conditional—Japan approval requires post‑market studies—and major markets (U.S., EU) still depend on ongoing pivotal data and regulatory decisions. Scaling manufacturing, reimbursement, and adoption across indications remain execution risks over the medium term.
Alpha Tau Medical Ltd News
DRTS FAQ
What was Alpha Tau Medical Ltd’s price range in the past 12 months?
Alpha Tau Medical Ltd lowest stock price was $2.81 and its highest was $11.62 in the past 12 months.
What is Alpha Tau Medical Ltd’s market cap?
Alpha Tau Medical Ltd’s market cap is $785.93M.
When is Alpha Tau Medical Ltd’s upcoming earnings report date?
Alpha Tau Medical Ltd’s upcoming earnings report date is Aug 18, 2026 which is in 76 days.
How were Alpha Tau Medical Ltd’s earnings last quarter?
Alpha Tau Medical Ltd released its earnings results on May 18, 2026. The company reported -$0.26 earnings per share for the quarter, missing the consensus estimate of -$0.124 by -$0.136.
Is Alpha Tau Medical Ltd overvalued?
According to Wall Street analysts Alpha Tau Medical Ltd’s price is currently Undervalued.
Does Alpha Tau Medical Ltd pay dividends?
Alpha Tau Medical Ltd does not currently pay dividends.
What is Alpha Tau Medical Ltd’s EPS estimate?
Alpha Tau Medical Ltd’s EPS estimate is -0.14.
How many shares outstanding does Alpha Tau Medical Ltd have?
Alpha Tau Medical Ltd has 88,009,735 shares outstanding.
What happened to Alpha Tau Medical Ltd’s price movement after its last earnings report?
Alpha Tau Medical Ltd reported an EPS of -$0.26 in its last earnings report, missing expectations of -$0.124. Following the earnings report the stock price went up 6.481%.
Which hedge fund is a major shareholder of Alpha Tau Medical Ltd?
Currently, no hedge funds are holding shares in DRTS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alpha Tau Medical Ltd Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.20 (51.93% Upside)
$12.20 (51.93% Upside)
Blogger Sentiment
Bullish
DRTS Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.9%
Last 30 Days ▲ 18.5%
Last 30 Days ▲ 18.5%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
204.77%
12-Months-Change
Fundamentals
Return on Equity
-73.23%
Trailing 12-Months
Asset Growth
34.41%
Trailing 12-Months
Company Description
Alpha Tau Medical Ltd
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.
DRTS Stock 12 Month Forecast
Average Price Target
$12.20
▲(51.93% Upside)
Technical Analysis
Larimar Therapeutics
―
Capricor Therapeutics
―
Benitec Biopharma
―
Aura Biosciences Inc
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
―
Insiders
0.05% Mutual Funds
2.32% Other Institutional Investors
97.28% Public Companies and
Individual Investors